Anti-Payload Antibody Products

Antibody-drug Conjugates & Payloads

Antibody-drug conjugates (ADCs) are a class of biopharmaceutical drugs designed to selectively deliver cytotoxic drugs to target cells while sparing normal, healthy tissues. ADCs consist of three key components: a monoclonal antibody, a linker molecule, and a cytotoxic payload. The cytotoxic payload of an ADC is typically a chemotherapeutic agent such as auristatins, maytansinoids, and calicheamicin. Once released inside the cancer cell, the cytotoxic drug interferes with essential cellular processes, ultimately leading to cell death. The payload is a crucial component of ADCs, as its effectiveness directly impacts the anti-cancer activity of the therapy.

ADC payloads typically consist of tubulin inhibitors and DNA-damaging agents. For example, tubulin inhibitors disrupt the microtubule network within the cell, preventing cell division and leading to cell death. DNA damaging agents directly target the DNA within the cancer cell, causing damage that prevents the cell from replicating and ultimately leads to cell death. Other common ADC payloads include topoisomerase inhibitors, RNA polymerase inhibitors, and DNA alkylating agents. Each of these payloads works by targeting different mechanisms within the cancer cell to inhibit its growth and induce cell death.

Payload Antibodies for ADC PK Analysis

The payloads of ADCs target different cellular processes or proteins, contributing to the overall efficacy of the ADC in fighting various diseases. Our anti-payload antibody products are designed to specifically target the payloads of ADCs. These antibodies are highly specific and can recognize and bind to the payload component of the ADC, allowing for accurate measurement of drug concentrations in various biological samples. These antibodies play a crucial role in quantifying and monitoring the levels of the payload, providing valuable information on the distribution and pharmacokinetics of the drug. This information is essential for optimizing drug dosing regimens, understanding drug mechanisms of action, and guiding the development of novel ADC therapies.

By using anti-payload antibodies, researchers can develop assays to quantify the concentration of the payload, assess the stability of ADCs in circulation, and evaluate the efficacy of drug delivery to target tissues. We offer a variety of monoclonal and polyclonal antibodies, as well as customizable conjugation options. In addition to anti-payload antibodies, we also offer anti-idiotype antibodies for assessing the pharmacokinetics, pharmacodynamics, and immunogenicity of the ADC. Our catalog covers the following targets including:

Whether you are conducting preclinical research, pharmacokinetic studies, or clinical trials involving ADCs, our anti-payload antibody products and anti-idiotype antibodies can serve as valuable tools for accurate and precise drug level measurements.